伊马替尼治疗小儿CML及对BCR-ABL融合基因转归的影响  

Imatinib for Pediatric CML and Its Effect on BCR-ABL Fusion Gene Conversion

作　　者：范慧 翟岩[1] 李宣萱 FAN Hui;ZHAI Yan;LI Xuanxuan(Henan Cancer Hospital,Zhengzhou,450000)

机构地区：[1]河南省肿瘤医院,450000

出　　处：《实用癌症杂志》2023年第3期507-509,共3页The Practical Journal of Cancer

摘　　要：目的 分析应用伊马替尼治疗小儿慢性粒细胞白血病(CML)及对BCR-ABL融合基因转归的影响。方法选取CML患儿86例,按随机数字表法分为研究组(n=43)和对照组(n=43),对照组予以第一代伊马替尼,研究组予以第二代伊马替尼。对比两组血液学疗效、BCR-ABL融合基因转归情况、血液学不良反应发生率、非血液学不良反应发生率、2年生存率。结果 研究组总缓解率[88.37%(38/43)]较对照组[65.12%(28/43)]高(P<0.05);研究组BCR-ABL^(IS)≤10%达标率[95.35%(41/43)]、BCR-ABL^(IS)≤0.0032%达标率[51.16%(22/43)]较对照组[67.44%(29/43)]、[20.93%(9/43)]高(P<0.05);研究组血液学不良反应发生率[6.98%(3/43)]与对照组[11.63%(5/43)]对比无显著差异(P>0.05);研究组非血液学不良反应发生率[4.65%(2/43)]与对照组[16.28%(7/43)]对比无显著差异(P>0.05);研究组2年生存率[97.50%(39/40)]与对照组[90.48%(38/42)]对比无显著差异(P>0.05)。结论 小儿CML应用第二代伊马替尼药物治疗,可提高血液学疗效,促进BCR-ABL融合基因转归,具有用药安全性,并可改善预后。Objective To analyze the effect of imatinib for pediatric chronic myelogenous leukemia(CML) and on the conversion of the BCR-ABL fusion gene.Methods 86 cases of CML children were selected and divided into the study group(n=43) and the control group(n=43).The control group received first generation imatinib and the study group received second generation imatinib.The hematological efficacy, BCR-ABL fusion gene outcome, incidence of hematologic adverse effects, incidence of non-hematologic adverse reactions, and 2-year survival rate were compared.Results The total remission rate [88.37%(38/343)] was higher than the control group [65.12%(28/43)](P<0.05);BCR-ABL^(IS)10% compliance rate [95.35%(41/43)] and BCR-ABL^(IS)0.0032% rate [51.16%(22/43)] were higher than the control group [67.44%(29/43)] and [20.93%(9/43)](P<0.05);The incidence of hematology adverse reactions between the study group [6.98%(3/43)] and [11.63%(5/43)] of the control group had no significant difference(P>0.05);The incidence of non-hematological adverse reactions in the study group [4.65%(2/43)] and [16.28%(7/43)] in the control group had no significant difference(P>0.05);The 2-year survival rates of the study group [97.50%(39/40)] and the control group [90.48%(38/42)] had no significant difference(P>0.05).Conclusion The second-generation imatinib for pediatric CML can improve the blood science efficacy, promote the BCR-ABL fusion gene conversion, have drug safety, and can improve the prognosis.

关 键 词：慢性粒细胞白血病 伊马替尼 BCR-ABL融合基因转归 血液学疗效 

分 类 号：R733.7[医药卫生—肿瘤]